In prostate cancer, Shan and colleagues identified constitutive nuclear and transiently increased cytoplasmic Trx1 oxidation by androgen but decreased Trx1 activities with the progression of prostate cancer, despite high levels of Trx1 protein expression in cancer cells [103]. Here, TXN is linked to prostate carcinoma.